Apr 11,2022

Symptom-related disruptions and rescue inhaler use decreases among Propeller users with asthma

In a recent Propeller Health study, the company observed that patients (n=1,679) with asthma who used a digital health platform had significant improvements in rescue inhaler use and self-reported activity rates over three months. Data was captured using Propeller’s digital health platform, which includes an inhaler sensor that passively collects medication use data and a mobile app that engages patients in chronic condition self-management.

CLINICAL STUDY

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 12,2022

Data Demonstrating Akili's Digital Therapeutic AKL-T03 Improves Cognition in Adults with Major Depressive Disorder

Akili Interactive (“Akili”), today announced that the American Journal of Psychiatry has published findings from the randomized STARS-MDD clinical trial (n=80) evaluating Akili’s AKL-T03 digital therapeutic as a potential treatment for attention impairments in adults with major depressive disorder (MDD) when used alongside antidepressant medication. Results of the study demonstrated that the addition of AKL-T03 to antidepressant therapy significantly improved sustained attention in adults diagnosed with MDD compared to the control group.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 15,2022

Therapeutic Alliance: Building Relationships With AI Therapy Chatbots

A recent peer-reviewed study in Frontiers of Wysa, an advanced conversational AI for mental health, shows people develop an emotional bond with its chatbot in much the same way people bond with a human therapist. The study of 1,205 people evaluated users of mental health app Wysa who were experiencing measured symptoms of anxiety or depression. The results show that within five days of using Wysa, the therapeutic alliance was comparable or better than scores found in traditional in-person cognitive behavioral therapy (CBT), in-person group therapy and internet-based tools for CBT.

CLINICAL STUDY

#chatbot

#cbt

View Analyst & Ambassador Comments
Go to original news
Apr 19,2022

Reulay Inc Announces Results From Study That Highlights the Effects of Reulay’s Digital Video and VR Platform for the Alleviation of Anxiety, Emotional Distress, and Distraction

Reulay, a research-backed mental health platform using AI to match anxiety states to brain-based interventions, today announced data that further underscores the effectiveness of Reulay’s digital video & VR therapeutics. The purpose of this pilot study was to evaluate the safety and use of a nature-based virtual reality (VR) experience among health care providers (HCP) during a pandemic. Twenty-four frontline HCP participated in this crossover pilot where the viewing order of the experiences were randomized. The study results showed that 96% of participants felt relaxed after seeing the imagery, and with respect to anxiety (as measured by the STAI Y1), the VR "Walk in the Woods" had the greatest reduction from pre to post followed by VR "Forest of Focus"

CLINICAL STUDY

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Apr 21,2022

Digital CBT could help Black women with insomnia

Digital cognitive behavioral therapy could help treat Black women with insomnia, according to a new study published in JAMA. In the single-blind, 3-arm randomized control study, participants received either an internet-delivered cognitive behavioral therapy (CBT) treatment called Sleep Healthy Using the Internet (SHUTi), a stakeholder-informed version for Black women or patient education information about sleep. Researchers found that study participants using an internet-based intervention for insomnia, with a tailored version for Black women and a standard version, significantly reduced their score on the insomnia severity index.

CLINICAL STUDY

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Apr 27,2022

Welldoc Presents Data Indicating Continuous Glucose Monitoring (CGM) Combined with a Digital Health Solution Leads to Significant Improvements in Glycemic Outcomes

Welldoc®, a digital health leader revolutionizing chronic care, today announced the presentation of data at the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), evaluating how the combination of real-time CGM (Dexcom G6) with a digital health solution (BlueStar platform) impacts glucose control for individuals with Type 2 diabetes not treated with insulin. Data show that the largest improvements took place in the intermediate users’ cohort, which had a TIR increase of 32% and a GMI improvement of 1.4. TIR improvements as low as 5% have been demonstrated to be clinically significant, therefore these data strongly support the hypothesis that combining rtCGM with a digital health solution can lead to enhanced glucose control and improved patient outcomes.

CLINICAL STUDY

#mobile app

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 27,2022

DarioHealth Presents New Clinical Research Demonstrating Improved Outcomes for Participants Using a Single Integrated Digital Solution to Manage Multiple Chronic Conditions

The study found that nearly two thirds of Dario participants with a BMI of more than 30 reduced their BMI by an average of 2.8 units with an average weight loss of 7.4% (p≤0.05). In addition, the study also examined a subgroup of Dario participants with BMIs greater than 30 and high-risk blood glucose readings of more than 180 mg/dL to understand the impact on both diabetes and weight management. This subgroup also demonstrated improved clinical outcomes, reducing their weight by an average of 4.9% and reducing their average blood glucose by 16.1% over a 12-months period.

CLINICAL STUDY

#mobile app

#coaching

#software

View Analyst & Ambassador Comments
Go to original news
Apr 28,2022

One Drop Presents Clinical Health Outcomes Demonstrating the Impact of Long-term Use of its Award-Winning Digital Platform

One Drop, a leader in precision health solutions for people living with diabetes and other chronic conditions, presented clinical health outcomes associated with long-term use with its award-winning digital platform at the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). New peer-reviewed research demonstrates that people with diabetes using One Drop sustained clinically and statistically significant reductions in average blood glucose beyond six months and one year, citing meaningful reductions in estimated A1C (eA1C).

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 04,2022

First-of-its-Kind Study Demonstrates Digital Therapeutic Significantly Improves Sleep and Mental Health for Stroke Patients

Big Health participated in a new, first-of-its-kind study in collaboration with the University of Oxford evaluating how a digital therapeutic for insomnia can benefit stroke patients with self-reported sleep issues. Preliminary outcomes found more than 48% of participants who utilized Sleepio – Big Health’s digital therapeutic for insomnia – experienced clinical improvement in sleep during post-stroke rehabilitation. In addition, the study found Sleepio users experienced less depression and anxiety 8-weeks post intervention. The study findings will be presented on May 4-6 at the European Stroke Organisation (ESO) conference being held in Lyon, France.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 05,2022

Cognoa Announces Nature Digital Medicine Publication of Pivotal Study Results Showing the Effectiveness of its Digital Diagnostic Device for Autism

Cognoa, a pediatric behavioral health company, today announced that npj Digital Medicine has published data from its pivotal study of the company’s AI-based diagnosis aid for autism spectrum disorder (ASD), Canvas Dx™. Canvas Dx is the first and only FDA-authorized diagnostic device designed to support providers in the diagnosis of autism in children aged 18-72 months in the primary care setting. The multi-site, prospective, blinded, method-comparison cohort study included 425 children, aged 18 to 72 months, with parental or primary care provider concern for developmental delay, in 14 sites across six states.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY